News & Events

Home | News | Ki-67 algorithm from Zeno Pathology in clinical study

Ki-67 algorithm from Zeno Pathology in clinical study

Together with Stacey Joosten et al. from the Netherlands Cancer Institute, WSK Medical collaborated on the clinical study “IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women”.

In this study, we compared pathologist assessed IHC-based Ki67 in samples from pre- and postmenopausal women in a neo-adjuvant, endocrine therapy focused trial and compared these results – among others – with our Artificial Intelligence (AI) Ki-67 algorithm that is part of our CE certified digital pathology solution Zeno Pathology.

The results from this study showed the added value of using AI in collaboration with doctors to assist in decision-making and analysis of complex, clinical data. The paper can be found here.

Share –

Related articles

Towards Better Health & Care – The Potential of AI – 24th of May in Amsterdam

European Congress on Digital Pathology (ECDP) – 15th-18th of June in Berlin

Zeno Pathology available in Founda Health platform

Demo //

Book a demo

Want to learn more about our solutions?

Our website only uses essential cookies. These cookies are used to make the website function properly. By continuing your visit on our website, you understand this. All our privacy related matters can be found in our privacy policy.